Has Rishi Singh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,476,743 in general payments to Rishi Singh, MD across 1,072 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rishi Singh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rishi Singh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rishi Singh, MD

Ophthalmology · Boston, MANPI 1750447660

Payments from drug & device makers

$2,476,743in general payments, 2019–2025

Across 1,072 payments — averaging $2310.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eyepoint US, Inc.$376K
Apellis Pharmaceuticals, Inc.$357K
Genentech, Inc.$281K
Regeneron Healthcare Solutions, Inc.$247K
Genentech USA, Inc.$147K
Carl Zeiss Meditec, Inc.$138K
plus $931K from 36 others

$198,783in research payments, 2019–2025

Across 136 payments — averaging $1461.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$109K
Regeneron$64K
Alimera Sciences, Inc.$15K
Novartis Pharma AG$10K
Novartis$840

What the payments were for

Consulting fees$873,27652%
Speaking & faculty fees$668,23040%
Travel & lodging$120,0757%
Food & beverage$27,8142%
Gifts$2800%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eyepoint US, Inc.	48	$376,352
Apellis Pharmaceuticals, Inc.	168	$357,070
Genentech, Inc.	68	$280,813
Regeneron Healthcare Solutions, Inc.	129	$247,218
Genentech USA, Inc.	83	$146,524
Carl Zeiss Meditec, Inc.	48	$137,881
Alcon	88	$108,731
Ocular Therapeutix, Inc.	27	$100,093
Novartis	56	$91,774
Regeneron	35	$84,549
Hoffmann-la Roche Limited	23	$62,544
AbbVie(2 entities)	36	$57,215
Astellas Pharma US Inc	42	$49,160
Aerie Pharmaceuticals, Inc.	9	$45,349
Alimera Sciences, Inc.	28	$44,013
Bausch & Lomb, A Division Of Bausch Health US, LLC	38	$40,424
Coherus Oncology, Inc.	12	$38,515
Novartis Pharma AG	9	$27,319
Bausch & Lomb Americas Inc.	34	$26,827
F. Hoffmann-la Roche AG	13	$26,107
Topcon Healthcare, Inc.	5	$23,888
Roche Products Limited	5	$22,301
Alcon Research LLC	6	$14,441
ANI Pharmaceuticals, Inc.	11	$13,992
Carl Zeiss Meditec USA, Inc.	8	$10,637
Biogen	6	$8,345
Kala Pharmaceuticals, Inc.	6	$7,255
Astellas Pharma Global Development	2	$6,543
Kyowa Kirin, Inc.	4	$5,916
Harrow Eye, LLC	8	$3,797
Optos, Inc.	1	$2,500
Oyster Point Pharma, Inc.	2	$2,142
Apotex Inc.	1	$2,000
Lumibird Medical Inc.	1	$1,500
Beaver-visitec International, Inc.	2	$1,400
Boehringer Ingelheim International GmbH	1	$975
Johnson & Johnson	2	$185
Intuitive Surgical	2	$168
Oculus Surgical Inc.	2	$161
Rayner Intraocular Lenses Limited	1	$50
Janssen Research & Development, LLC	1	$38
Actelion Pharmaceuticals US, Inc.	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EYLEA$197,997
Syfovre$179,436
VABYSMO$176,455
BEOVU$85,968
EYLEA HD$84,627
Constellation$80,859
Izervay$54,831
OZURDEX$46,541
YUTIQ$45,884
EYP-1901$43,262
Lucentis$43,129
CIRRUS HD-OCT$42,550
Cimerli$38,465
NGENUITY$28,690
Iluvien$24,004
CLARUS$23,780
Alcon Greishaber Finesse$20,089
OPMI Lumera 700$15,807
FORUM$14,020
PURIFIED CORTROPHIN GEL$13,520

How this compares

$2,476,743 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$5,478

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Boston

Jennifer SunBoston$4.2M
Lloyd AielloBoston$3.1M
Jack GreinerBoston$523K
Reza DanaBoston$510K
Adam RogersBoston$316K
Bonnie HendersonBoston$279K
David FriedmanBoston$259K
Dean EliottBoston$250K
Michael RaizmanBoston$237K
Mina FarahaniBoston$233K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →